Steward Financial Group’s Blueprint Medicines BPMC Stock Holding History

Steward Financial Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-19	Closed	–	–	240
2022 Q2	$0	Buy	+19	New	+$1.11K	﹤0.01%	1001

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Steward Financial Group's BPMC Position: Q3 2022 in Review

Steward Financial Group sold out of Blueprint Medicines (BPMC) in Q3 2022, closing a stake of 19 shares.

Steward Financial Group first reported a position in BPMC in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

Steward Financial Group reported no remaining Blueprint Medicines position as of Q3 2022 after selling out during the quarter.
Steward Financial Group sold 19 Blueprint Medicines shares in Q3 2022.
Steward Financial Group first reported a position in Blueprint Medicines in Q2 2022 and held it in 1 quarter.
Steward Financial Group's Blueprint Medicines position peaked at $0 in Q2 2022.
240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on Steward Financial Group's 13F filing for Q3 2022, filed 7 Nov 2022.